Skip to main content

Table 3 Incidence of solicited systemic adverse events per vaccine type per dose

From: Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months

  

First dose

Second dose

Third dose

  

15 μg MSP3

30 μg MSP3

Engerix B

15 μg MSP3

30 μg MSP3

Engerix B

15 μg MSP3

30 μg MSP3

Engerix B

  

N = 15

N = 15

N = 15

N = 15

N = 15

N = 15

N = 15

N = 15

N = 15

Symptom

Intensity

n

%

n

%

n

%

n

%

n

%

n

%

n

%

n

%

n

%

Any

Overall

6

40

6

40

5

53

1

6.7

0

0

2

13

0

0

1

6.7

0

0

 

Grade 3

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

 

Related

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Fever

Overall

2

13

2

13

2

13

1

6.7

0

0

2

13

0

0

1

6.7

0

0

 

Grade 3

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

 

Related

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Irritability

Overall

2

13

0

0

2

13

0

0

0

0

0

0

0

0

0

0

0

0

 

Grade 3

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

 

Related

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Drowsiness

Overall

1

6.7

1

6.7

1

6.7

0

0

0

0

0

0

0

0

0

0

0

0

 

Grade 3

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

 

Related

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Loss of appetite

Overall

5

33

5

33

0

0

0

0

0

0

0

0

0

0

0

0

0

0

 

Grade 3

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

 

Related

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0